Research ReportsLupin - New Drugs Approvals Will Boost Future Prospects: Axis Securities
ADVERTISEMENT
Lupin - New Drugs Approvals Will Boost Future Prospects: Axis Securities
Niche product approvals and a strong pipeline of new drugs could drive revenue/profit after tax compound annual growth rate by 10%/19.5% over FY24E-FY26E.
Lupin's manufacturing site at Visakhapatnam. (Source: Company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.